Personalized ADHD drug shows promise in early trial for teens

NCT ID NCT02286817

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study tested a drug called NFC-1 in 30 adolescents aged 12-17 with ADHD who also have specific genetic changes affecting brain receptors. The goal was to check the drug's safety and how the body processes it, while also looking for signs it might reduce ADHD symptoms. Participants received a single dose followed by four weeks of daily treatment, with results compared to a placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NFC-1 (a drug targeting glutamate receptors in the brain)
What this could lead to
If successful, this could point toward a personalized treatment for ADHD in teens with specific genetic changes.
What could go wrong
This is an early Phase 1 trial with only 30 participants, so results may not apply widely. The drug may not improve ADHD symptoms or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Thomas Jefferson University, Clinical Research Unit

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.